X-linked Agammaglobulinemia (XLA)
An inherited immune disorder in boys caused by BTK gene mutations, leading to absent antibody-producing B cells and recurrent bacterial infections.
- Lifelong management available
- Immunoglobulin replacement effective
- Genetic testing confirms diagnosis
- Most Common In
- Male infants and young boys, X-linked inheritance
- Typical Onset
- After maternal antibody protection wanes (around 6 months)
- Affected Gene
- BTK (Bruton tyrosine kinase)
- Advanced Therapies
- Immunoglobulin replacement therapy
What Is X-linked Agammaglobulinemia?
X-linked Agammaglobulinemia (XLA) is an inherited primary immunodeficiency caused by mutations in the BTK gene, which encodes Bruton tyrosine kinase โ an enzyme essential for the maturation of B lymphocytes, the cells responsible for producing antibodies. Without functional BTK, B cells fail to develop normally, resulting in very low or absent levels of all major immunoglobulin classes (IgG, IgA, IgM).
Because antibodies are critical for fighting many bacterial infections, boys with XLA experience recurrent and sometimes severe bacterial infections, typically beginning after maternal antibodies (passed during pregnancy) wane around six months of age. Common sites of infection include the sinuses, ears, lungs, and gastrointestinal tract.
XLA is inherited in an X-linked recessive pattern, so it almost exclusively affects boys, who inherit the altered BTK gene from a carrier mother. With lifelong immunoglobulin replacement therapy and prompt treatment of infections, most boys and men with XLA can lead active, productive lives.
Clinical Variants
XLA is generally a single well-defined clinical entity, but presentations can vary by age of onset and degree of residual B-cell function.
Symptoms and Warning Signs
Boys with XLA typically develop recurrent bacterial infections after the protective effect of maternal antibodies declines.
Causes and Risk Factors
XLA is a purely genetic condition; it is not caused by environmental exposures or lifestyle factors.
Diagnosis and Investigations
Diagnosis of XLA combines clinical history, immunoglobulin and B-cell testing, and genetic confirmation.
Disease Severity Stratification
XLA is not formally staged, but clinicians classify severity based on infection history and degree of organ damage at diagnosis.
Standard Treatment Approach
Lifelong immunoglobulin replacement therapy is the cornerstone of XLA management, alongside prompt treatment of infections.
Advanced and Emerging Treatment Options
While immunoglobulin replacement remains standard of care, research into more definitive approaches for XLA continues.
Immunoglobulin Replacement
Subcutaneous immunoglobulin (SCIg)
Allows more frequent, lower-volume home infusions with steadier antibody levels compared to intravenous dosing for some patients.
Gene Therapy
Investigational BTK gene therapy
Early-stage research is exploring gene correction approaches to restore BTK function and B-cell development.
Cellular Therapy
Hematopoietic stem cell transplant
Not standard of care for XLA given the effectiveness of immunoglobulin replacement, but has been used rarely in select complex cases.
Biomarkers and Precision Testing
Immunologic and genetic markers are central to diagnosing XLA and monitoring treatment.
When a Second Opinion May Be Important
Specialist immunology input can be valuable at several points in the management of XLA.
Clinical Trials and Research
Prognosis and Key Outcome Factors
With early diagnosis and consistent immunoglobulin replacement therapy, most boys and men with XLA achieve good long-term health and a normal life expectancy.
Supportive Care and Living With XLA
Living with XLA involves consistent medical management alongside practical strategies for daily life.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families of boys and men with XLA access specialist immunology review, coordinate immunoglobulin replacement planning, and connect with experienced primary immunodeficiency centers.
Get a free case reviewFrequently Asked Questions
XLA is an inherited immunodeficiency caused by BTK gene mutations, resulting in absent antibody-producing B cells and recurrent bacterial infections.
Early signs include recurrent ear infections, sinusitis, and pneumonia beginning around six months of age in male infants.
XLA almost exclusively affects boys, since it requires a mutated BTK gene on the X chromosome; female carriers are generally unaffected.
There is no cure, but lifelong immunoglobulin replacement therapy effectively controls infections and allows most patients to live active, healthy lives.
Treatment centers on regular intravenous or subcutaneous immunoglobulin infusions, combined with prompt treatment of breakthrough infections.
Diagnosis combines low or absent immunoglobulin levels, absent B cells on blood testing, and confirmatory BTK gene sequencing.
Patients with XLA cannot mount a normal antibody response and are at risk of severe disease from live vaccines, particularly live oral polio vaccine.
Yes โ repeated respiratory infections, especially if diagnosis is delayed, can lead to chronic lung disease such as bronchiectasis.
Genetic counseling and carrier testing are recommended for female relatives, and any future male relatives should be tested promptly.
Yes. CancerFax can help coordinate medical report review, connect families with specialist immunology centers, support second opinion requests, and facilitate access to immunoglobulin replacement programs, including cross-border coordination when needed.
Get Expert Guidance on XLA Treatment
Our team can help you connect with specialist immunology centers for diagnosis confirmation and immunoglobulin replacement planning.